IOV News

Iovance’s Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma

First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy

August 18, 2025Approval

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025

IOV

$60.0M in 2Q25 Total Product Revenue

August 7, 2025Earnings